Wechselwirkungen · Vocabria
Vocabria 30 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-143451 · Präparat HOS-099004
Cabotegravir is primarily metabolised by uridine diphosphate glucuronosyl transferase (UGT) 1A1 and to a lesser extent by UGT1A9. Medicinal products which are strong inducers of UGT1A1 or UGT1A9 are expected to decrease cabotegravir plasma concentrations leading to lack of efficacy (see section 4.3 and table 2 below). In poor metabolizers of UGT1A1, representing a maximum clinical UGT1A1 inhibition, the mean AUC, Cmax and Ctau of oral cabotegravir increased by up to 1.5-fold. The impact of an UGT1A1 inhibitor may be slightly more pronounced, however, considering the safety margins of cabotegravir, this increase is not expected to be clinically relevant. No dosing adjustments for Vocabria are, therefore, recommended in the presence of UGT1A1 inhibitors (e.g. atazanavir, erlotinib, sorafenib).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) erlotinib (HOS-113527) sorafenib (HOS-115745) uridine (HOS-085192)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-09T14:50:00Z · SHA-256 5a6802905e0f35577ea123d161d3a8ece2c09d33762d2d6c349b5a0a60e5d7b9 · Passage 1e445b8b5d3128b645a028a6a1b74a9b9d718d3e66b9e3a06f7e816e845db20d · Zeichen 290–1092 im Abschnitt